trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Praziquantel is a drug used in mass drug administration programs for the treatment of schistosomiasis and the prevention of morbidity.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
12 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Praziquantel is a drug used in mass drug administration programs for the treatment of schistosomiasis and the prevention of morbidity?

Yes. Praziquantel is widely recognized and utilized as the primary drug in mass drug administration programs aimed at treating schistosomiasis and preventing associated morbidity.

Verdict: SUPPORTED · 12 sources for, 0 against · Last checked

The analysis

Every retrieved paper explicitly states or assumes that praziquantel is the standard medication used in mass drug administration (MDA) programs for treating schistosomiasis and controlling morbidity in endemic regions. The evidence universally supports the claim without any contradictory findings regarding its primary purpose.

Evidence for · 12
2024
Refers to hundreds of millions of doses of praziquantel administered through mass drug administration campaigns in schistosomiasis-endemic settings.
Get citation
Danso-Appiah, A., Owiredu, D., & Akuffo, K. O. (2024). Praziquantel-related visual disorders among recipients in mass drug administration campaigns in schistosomiasis endemic settings: Systematic review and meta-analysis protocol. doi.org. https://doi.org/10.1371/journal.pone.0300384

See more details
More for · 11
2023
Investigates the coverage and predictors of the uptake of mass drug administration of praziquantel chemotherapy for schistosomiasis.
Get citation
Kiesolo, F. N., Sampa, M., Moonga, G., Michelo, C., & Jacobs, C. (2023). Coverage and predictors of the uptake of the mass drug administration of praziquantel chemotherapy for schistosomiasis in a selected urban setting in Zambia. doi.org. https://doi.org/10.3389/fepid.2023.1168282

2025
Assesses schistosomiasis infection levels years after mass drug administration with praziquantel.
Get citation
Imalele, E. E., Braide, E. I., Emanghe, U. E., & Osondu-Anyanwu, C. (2025). The burden of schistosomiasis among school-aged children in Ogoja, Nigeria: current level of infection years after mass drug administration with Praziquantel. doi.org. https://doi.org/10.4314/ahs.v24i4.9

2026
Discusses regular mass drug administration with praziquantel against urogenital schistosomiasis implemented over two decades.
Get citation
S, K., NJ, v. D., NC, N., T, P., MN, A., KR, S., M, D., S, J., SM, A., AM, E., BL, W., LE, C., & SM, A. (2026). 20+ years of mass drug administration against urogenital schistosomiasis on the Zanzibar islands: Is praziquantel still efficacious?. doi.org. https://doi.org/10.64898/2026.08.13.26360376

2026
Notes that praziquantel is a key component of schistosomiasis control programs recommended by the WHO.
Get citation
HM, M., T, E., & I, A. (2026). Therapeutic Management of Schistosomiasis in Pregnancy: A Comprehensive Review of Praziquantel Safety and Clinical Outcomes.. doi.org. https://doi.org/10.3390/biomedicines14092018

2026
Acknowledges that praziquantel is the recommended treatment utilized in mass drug administration programs.
Get citation
M, K., RD, M., T, R., & N, S. (2026). Barriers in managing maternal schistosomiasis: a qualitative study of healthcare providers in Tanzania.. doi.org. https://doi.org/10.1093/inthealth/ihag001

2026
Evaluates the feasibility of preventative chemotherapy with praziquantel in young children.
Get citation
E, M., AS, A., EA, N., D, S., SD, B., EA, S., N, D., F, A., G, S., H, A., G, H., M, A., P, A., & G, G. (2026). Non-Participation Undermines Mass Drug Administration Effectiveness and Sustains Urogenital Schistosomiasis Transmission in an Endemic Community in Ghana. doi.org. https://doi.org/10.64898/2026.08.03.26359546

2026
Explores implementation fidelity of school-based preventive chemotherapy using praziquantel for schistosomiasis control.
Get citation
V, M., DK, A., S, R., A, G., M, L., F, F., A, R., JC, H., L, S., A, B., T, R., P, R., O, T., AO, Z., T, R., HG, R., EF, R., A, G., I, K., CF, R., J, M., RA, R., & D, F. (2026). Feasibility of paediatric schistosomiasis prevention with praziquantel, Madagascar.. doi.org. https://doi.org/10.2471/blt.25.295521

2026
Notes that mass drug administration using praziquantel is central to efforts to eliminate schistosomiasis.
Get citation
H, M., BJ, M., M, V., & FN, G. (2026). Contextual barriers and facilitators influencing implementation fidelity of school-based preventive chemotherapy for schistosomiasis: A qualitative study in two endemic districts in the Central Region, Ghana.. doi.org. https://doi.org/10.1371/journal.pone.0348920

2026
Evaluates the costs and implementation of community-based mass drug administration for schistosomiasis control using praziquantel.
Get citation
P, O., FD, C., J, O., E, O., BH, O., M, M., WL, C., T, A., & EM, N. (2026). Pooled amplicon sequencing for characterizing mutations in the praziquantel molecular target TRPM  <sub>PZQ</sub>  in schistosome populations from Western Kenya. doi.org. https://doi.org/10.64898/2026.08.04.742841

2026
Examines schistosomiasis control implications following mass praziquantel administration campaigns.
Get citation
JM, B., A, K., E, G., I, M., R, P., CE, C., CG, M., S, K., C, K., A, F., A, M., HD, M., & AT, M. (2026). Cost analysis of implementing community-based mass drug administration for schistosomiasis control among adult individuals using community drug distributors in Ukerewe district council, North-Western Tanzania.. doi.org. https://doi.org/10.1371/journal.pntd.0014470

2026
Get citation
Okete, J. A., Etta, E. E., Ikika, P. E., Akpe, T. E., & Onoja, B. O. (2026). Occurrence of snail intermediate host of schistosomiasis: implications for schistosomiasis control based on mass drug administration of praziquantel in Benue State, Nigeria. doi.org. https://doi.org/10.64898/2026.01.22.701117

What does the evidence say?

Every retrieved paper explicitly states or assumes that praziquantel is the standard medication used in mass drug administration (MDA) programs for treating schistosomiasis and controlling morbidity in endemic regions. The evidence universally supports the claim without any contradictory findings regarding its primary purpose.

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work